Clinical Trials Browser

Phase 3 × Has results × Ovarian Neoplasms × Clear all

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Phase 3 Active not recruiting

733 enrolled 21 charts 2 FDA

Ovarian Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Phase 3 Active not recruiting

643 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Active not recruiting

579 enrolled 17 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03602859 2025-12-31

FIRST

Phase 3 Active not recruiting

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT00565851 2025-12-30

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Active not recruiting

1,052 enrolled 27 charts

Brenner Tumor, Carcinoma, Adenocarcinoma, Mucinous, Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT01844986 2025-12-10

SOLO-1

Phase 3 Active not recruiting

450 enrolled 18 charts 1 FDA

Pathologic Complete Response, Ovarian Neoplasms

NCT01081262 2025-11-25

Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Phase 3 Active not recruiting

50 enrolled 13 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03740165 2025-10-22

KEYLYNK-001

Phase 3 Active not recruiting

1,367 enrolled 29 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01874353 2025-08-03

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3 Active not recruiting

327 enrolled 21 charts 1 FDA

Ovarian Neoplasms

NCT02470585 2024-10-26

VELIA

Phase 3 Terminated

1,140 enrolled 29 charts

Ovarian Neoplasms

NCT03635489 2024-10-03

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

100 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Ovarian Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Phase 3 Completed

566 enrolled 40 charts

Ovarian Neoplasms

NCT01968213 2023-06-09

ARIEL3

Phase 3 Completed

564 enrolled 18 charts 1 FDA

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Phase 3 Completed

349 enrolled 29 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01847274 2023-06-02

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Phase 3 Completed

596 enrolled 65 charts

Ovarian Neoplasms

NCT03642132 2023-04-06

JAVELIN OVARIAN PARP100

Phase 3 Terminated

79 enrolled 18 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03038100 2023-02-17

IMagyn050

Phase 3 Completed

1,301 enrolled 22 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Phase 3 Terminated

1,100 enrolled 30 charts

Ovarian Neoplasms

NCT01905592 2022-11-15

BRAVO

Phase 3 Terminated

216 enrolled 19 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT02282020 2022-07-26

SOLO3

Phase 3 Completed

266 enrolled 31 charts

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Phase 3 Completed

140 enrolled 11 charts 1 FDA

Ovarian Neoplasms

NCT00954174 2021-09-30

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 3 Unknown

637 enrolled 18 charts

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00866697 2021-02-16

Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 3 Completed

940 enrolled 23 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

Phase 3 Completed

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02718417 2020-07-14

JAVELIN OVARIAN 100

Phase 3 Terminated

998 enrolled 39 charts

Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

Phase 3 Completed

442 enrolled 33 charts

Ovarian Neoplasms

NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Completed

1,873 enrolled 17 charts 1 FDA

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00011986 2019-04-16

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase 3 Completed

4,312 enrolled 14 charts

Ovarian Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 3 Completed

581 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01015118 2017-12-07

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Phase 3 Completed

1,366 enrolled 17 charts

Ovarian Neoplasms, Peritoneal Neoplasms

NCT00434642 2017-08-09

OCEANS

Phase 3 Completed

484 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01684878 2017-05-23

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

Phase 3 Completed

208 enrolled 19 charts

Ovarian Neoplasms

NCT02311907 2017-02-23

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

Phase 3 Completed

195 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Pain, Neurotoxicity Syndromes

NCT01704651 2016-10-24

Accelerating Gastrointestinal Recovery

Phase 3 Completed

146 enrolled 11 charts

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

NCT01239732 2016-06-10

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Phase 3 Completed

1,021 enrolled 11 charts

Ovarian Neoplasms

NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Phase 3 Terminated

32 enrolled 13 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Phase 3 Completed

672 enrolled 14 charts

Ovarian Neoplasms

NCT00245050 2011-12-30

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer

Phase 3 Completed

34 enrolled 9 charts

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Drug-Related Side Effects and Adverse Reactions

NCT00191646 2011-03-04

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

Phase 3 Completed

919 enrolled 18 charts

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms